CA2474794A1 - Method of providing prophylaxis for tuberculosis in hiv positive individuals - Google Patents
Method of providing prophylaxis for tuberculosis in hiv positive individuals Download PDFInfo
- Publication number
- CA2474794A1 CA2474794A1 CA002474794A CA2474794A CA2474794A1 CA 2474794 A1 CA2474794 A1 CA 2474794A1 CA 002474794 A CA002474794 A CA 002474794A CA 2474794 A CA2474794 A CA 2474794A CA 2474794 A1 CA2474794 A1 CA 2474794A1
- Authority
- CA
- Canada
- Prior art keywords
- mycobacterium
- cancer
- adjuvant
- formulation
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000008827 tuberculosis Diseases 0.000 title claims abstract description 41
- 238000000034 method Methods 0.000 title claims abstract description 19
- 238000011321 prophylaxis Methods 0.000 title abstract description 11
- 241001494992 Mycobacterium indicus pranii Species 0.000 claims abstract description 57
- 229960001005 tuberculin Drugs 0.000 claims description 28
- 230000036039 immunity Effects 0.000 claims description 20
- 239000003755 preservative agent Substances 0.000 claims description 17
- 230000002335 preservative effect Effects 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000002255 enzymatic effect Effects 0.000 claims description 4
- 229910002651 NO3 Inorganic materials 0.000 claims description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 3
- 108010046334 Urease Proteins 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 230000001717 pathogenic effect Effects 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 238000000638 solvent extraction Methods 0.000 claims description 3
- 241001506930 atypical mycobacterium Species 0.000 claims description 2
- 239000004202 carbamide Substances 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims description 2
- 230000002503 metabolic effect Effects 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000000053 physical method Methods 0.000 claims description 2
- 238000000527 sonication Methods 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 5
- 239000002480 mineral oil Substances 0.000 claims 4
- 235000010446 mineral oil Nutrition 0.000 claims 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 claims 2
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims 2
- 229920003345 Elvax® Polymers 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 239000000020 Nitrocellulose Substances 0.000 claims 2
- 108010073443 Ribi adjuvant Proteins 0.000 claims 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 claims 2
- 159000000013 aluminium salts Chemical class 0.000 claims 2
- 229910000329 aluminium sulfate Inorganic materials 0.000 claims 2
- 239000001506 calcium phosphate Substances 0.000 claims 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 2
- 235000011010 calcium phosphates Nutrition 0.000 claims 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims 2
- 229920001220 nitrocellulos Polymers 0.000 claims 2
- 229940049964 oleate Drugs 0.000 claims 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims 2
- 229930182490 saponin Natural products 0.000 claims 2
- 150000007949 saponins Chemical class 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 229940031439 squalene Drugs 0.000 claims 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 238000011275 oncology therapy Methods 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 abstract description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 239000003814 drug Substances 0.000 description 10
- HXQVQGWHFRNKMS-UHFFFAOYSA-M ethylmercurithiosalicylic acid Chemical compound CC[Hg]SC1=CC=CC=C1C(O)=O HXQVQGWHFRNKMS-UHFFFAOYSA-M 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 239000008215 water for injection Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000470 constituent Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241000187644 Mycobacterium vaccae Species 0.000 description 5
- 230000024932 T cell mediated immunity Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000006997 middlebrook medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005865 ionizing radiation Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000187478 Mycobacterium chelonae Species 0.000 description 2
- 241000186365 Mycobacterium fortuitum Species 0.000 description 2
- 208000036981 active tuberculosis Diseases 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 101150004367 Il4i1 gene Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 241000983409 Microbacterium terrae Species 0.000 description 1
- 241001036794 Microsorum maximum Species 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187473 Mycobacterium aurum Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000187486 Mycobacterium flavescens Species 0.000 description 1
- 241000187485 Mycobacterium gastri Species 0.000 description 1
- 241001509451 Mycobacterium genavense Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241001147828 Mycobacterium haemophilum Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187493 Mycobacterium malmoense Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187491 Mycobacterium nonchromogenicum Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241001147832 Mycobacterium shimoidei Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187476 Mycobacterium triviale Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004970 cd4 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 208000037837 multi-bacillary leprosy Diseases 0.000 description 1
- 208000015305 multibacillary leprosy Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Present invention relates to the method providing prophylaxis for tuberculosis in HIV positive individuals. According to present invention, vaccine made from 'Mycobacterium w' (Mw) is found to be useful in providing prophylaxis against tuberculosis in HIV positive individuals.
Description
THE METHOD PROVIDING PROPHYLAXIS FOR TUBERCULOSIS IN HIV
POSITIVE INDIVIDUALS
Tuberculosis is a major communicable disease worldwide. It is caused by mycobacterium tuberculosis. It is a major cause of morbidity and mortality worldwide which includes developing countries as well as developed countries. This is happening inspite of availability of effective chemotherapy.
The problem of tuberculosis has gained more attention recently due to spreading epidemic of tuberculosis worldwide. The immunity in HIV is compromised and it makes the individual more vulnerable to various infectious disease particularly tuberculosis. The decrease in immunity is more pronounced for cell mediated immunity than humoral immunity. The incidence of tuberculosis is much more in HIV positive individuals compared to normal subjects. It varies from 32% in Brazil to 64% in India in HIV +ve individuals.
The increased risk of tuberculosis can also be judged by the fact that in normal individuals risk of tuberculosis is 5% in 5 years compared to 8% in in first year in HIV positive. Similarly if life time risk of developing tuberculosis is one in normal individuals than it is 113 in HIV positive individuals..
Thus there is a greater need to provide prophylaxis against tuberculosis in HIV positive individuals.
The immunity against tuberculosis is judged by a test called tuberculin test.
It is performed by injecting antigens [purified protein derivative (PPD)] of mycobacterium tuberculosis. In persons having immunity against tuberculosis there develops reaction at site of injection, which is read at 48 to 72 hours after infection. The reaction which develops at injection site consists of a raised, red, and hard (indurate ) area in the skin. This is indicative of presence of cell mediated immunity against tuberculosis., The immunity as detected by this method is found in individuals who are given BCG vaccination or exposed to tuberculosis organisms.
I
CONFIRMATION COPY
The only known vaccine in use for providing prophylaxis against tuberculosis is BCG. The BCG contains live microorganisms and so it can not be given to immunocompromised individuals like HIV positive individuals.
The current recommendations are to provide prophylaxis to HIV positive individuals by chemotherapeutic agents like Isoniazid, Rifampicin etc. There-is no accepted method for providing immunity against tuberculosis. Thus there is unmet requirement for providing immunity against tuberculosis in HIV positive individuals.
US patents 54724144, 5985287, 6160093, 6001361 describes use of mycobacterium vaccae or its various components effective for the purpose of providing immunity against tuberculosis in animals.
US patent 6210684 and WO 9406466 describes use of mycobacterium vaccae for treatment or prophylaxis of AIDS.
However when used in human who are HIV positive mycobacterium vaccae fails to provide immunity against tuberculosis even after 3 to 5 doses.
(Johnson D et al. Vaccine 1999, 17(20-21): 2583-7: Marsha BJ et. al. Am J , Med Sci_1997, 313(6):377-83,: Waddell RD, Clin Infect Dis 2000, 30 Suppl 3a309-15) Thus the need to provide immunity against tuberculosis in HIV positive individuals is not met.
The failure to elicit immune response with mycobacterium vaccae may be due to inability of depleting CD4 cells to function in a manner to improve cell mediated immunity against tuberculosis which is judged by tuberculin conversion.
Surprisingly according to present invention it is observed that it is possible to provide a pharmaceutical composition for immunity against tuberculosis in HIV positive individuals. The process of preparing pharmaceutical composition for this purpose involves use of mycobacterium w.
POSITIVE INDIVIDUALS
Tuberculosis is a major communicable disease worldwide. It is caused by mycobacterium tuberculosis. It is a major cause of morbidity and mortality worldwide which includes developing countries as well as developed countries. This is happening inspite of availability of effective chemotherapy.
The problem of tuberculosis has gained more attention recently due to spreading epidemic of tuberculosis worldwide. The immunity in HIV is compromised and it makes the individual more vulnerable to various infectious disease particularly tuberculosis. The decrease in immunity is more pronounced for cell mediated immunity than humoral immunity. The incidence of tuberculosis is much more in HIV positive individuals compared to normal subjects. It varies from 32% in Brazil to 64% in India in HIV +ve individuals.
The increased risk of tuberculosis can also be judged by the fact that in normal individuals risk of tuberculosis is 5% in 5 years compared to 8% in in first year in HIV positive. Similarly if life time risk of developing tuberculosis is one in normal individuals than it is 113 in HIV positive individuals..
Thus there is a greater need to provide prophylaxis against tuberculosis in HIV positive individuals.
The immunity against tuberculosis is judged by a test called tuberculin test.
It is performed by injecting antigens [purified protein derivative (PPD)] of mycobacterium tuberculosis. In persons having immunity against tuberculosis there develops reaction at site of injection, which is read at 48 to 72 hours after infection. The reaction which develops at injection site consists of a raised, red, and hard (indurate ) area in the skin. This is indicative of presence of cell mediated immunity against tuberculosis., The immunity as detected by this method is found in individuals who are given BCG vaccination or exposed to tuberculosis organisms.
I
CONFIRMATION COPY
The only known vaccine in use for providing prophylaxis against tuberculosis is BCG. The BCG contains live microorganisms and so it can not be given to immunocompromised individuals like HIV positive individuals.
The current recommendations are to provide prophylaxis to HIV positive individuals by chemotherapeutic agents like Isoniazid, Rifampicin etc. There-is no accepted method for providing immunity against tuberculosis. Thus there is unmet requirement for providing immunity against tuberculosis in HIV positive individuals.
US patents 54724144, 5985287, 6160093, 6001361 describes use of mycobacterium vaccae or its various components effective for the purpose of providing immunity against tuberculosis in animals.
US patent 6210684 and WO 9406466 describes use of mycobacterium vaccae for treatment or prophylaxis of AIDS.
However when used in human who are HIV positive mycobacterium vaccae fails to provide immunity against tuberculosis even after 3 to 5 doses.
(Johnson D et al. Vaccine 1999, 17(20-21): 2583-7: Marsha BJ et. al. Am J , Med Sci_1997, 313(6):377-83,: Waddell RD, Clin Infect Dis 2000, 30 Suppl 3a309-15) Thus the need to provide immunity against tuberculosis in HIV positive individuals is not met.
The failure to elicit immune response with mycobacterium vaccae may be due to inability of depleting CD4 cells to function in a manner to improve cell mediated immunity against tuberculosis which is judged by tuberculin conversion.
Surprisingly according to present invention it is observed that it is possible to provide a pharmaceutical composition for immunity against tuberculosis in HIV positive individuals. The process of preparing pharmaceutical composition for this purpose involves use of mycobacterium w.
Mycobacterium w is found to be useful in management of leprosy. It converts lepromin negative individuals to lepromin positive status. It also reduces the duration of therapy required for cure of multibacillary leprosy.
The pharmaceutical composition made as per present invention is found to be effective in providing immunity against tuberculosis in HIV positive individuals as judged by tuberculin test.
Summary of the invention According to present invention, vaccine made from 'Mycobacterium w' (MW) is found to be useful in providing prophylaxis against tuberculosis in HIV
positive individuals. It is observed that administration of mycobacterium w containing vaccine is capable of converting tuberculin negative and hiv positive individuals into tuberculin positive status. These effects have been found in patients suffering from tuberculosis also. These effects are also seen in patients who are suffering from HIV infection with or without AIDS and with or without associated tuberculosis.
Mycobacterium w used in the present invention is.~ a non-pathogenic, cultivable, atypical mycobacterium, - with biochemical properties and fast growth characteristics resembling those belonging to Runyons group IV class of Mycobacteria in its metabolic and growth properties but is not identical to those strains currently listed in this group. It is therefore thought that (MW) is an entirely new strain.
The species identity of Mw has been defined by polymerase chain reaction DNA sequence determination and differentiated from thirty other species of mycobacteria. It however differs from those presently listed in this group in on respect or the other. By base sequence analysis of a polymorphic region of pattern analysis, it has been established that MW is a unique species distinct from many other known mycobacterial species examined which are: M.
avium, M. intracellulare, M. scrofulaceum, M. kansasii, M. gastri, M.
gordonae, M. shimoidei, M. malmoense, M. haemophilum, M. terrae, M.
nonchromogenicum, M. triviale, M. marinum, M. flavescens, M. simian, M.
The pharmaceutical composition made as per present invention is found to be effective in providing immunity against tuberculosis in HIV positive individuals as judged by tuberculin test.
Summary of the invention According to present invention, vaccine made from 'Mycobacterium w' (MW) is found to be useful in providing prophylaxis against tuberculosis in HIV
positive individuals. It is observed that administration of mycobacterium w containing vaccine is capable of converting tuberculin negative and hiv positive individuals into tuberculin positive status. These effects have been found in patients suffering from tuberculosis also. These effects are also seen in patients who are suffering from HIV infection with or without AIDS and with or without associated tuberculosis.
Mycobacterium w used in the present invention is.~ a non-pathogenic, cultivable, atypical mycobacterium, - with biochemical properties and fast growth characteristics resembling those belonging to Runyons group IV class of Mycobacteria in its metabolic and growth properties but is not identical to those strains currently listed in this group. It is therefore thought that (MW) is an entirely new strain.
The species identity of Mw has been defined by polymerase chain reaction DNA sequence determination and differentiated from thirty other species of mycobacteria. It however differs from those presently listed in this group in on respect or the other. By base sequence analysis of a polymorphic region of pattern analysis, it has been established that MW is a unique species distinct from many other known mycobacterial species examined which are: M.
avium, M. intracellulare, M. scrofulaceum, M. kansasii, M. gastri, M.
gordonae, M. shimoidei, M. malmoense, M. haemophilum, M. terrae, M.
nonchromogenicum, M. triviale, M. marinum, M. flavescens, M. simian, M.
szulgai, M. xenopi, M. asciaticum, M. aurum, M. smegmatis, M. vaccae, M.
fortuitum subsp fortuitum, M. fortuitum subsp. Peregrinum, M. chelonae subsp. Chelonae, M. chelonae subsp. Abscessus, M. genavense, M.
tuberculosis, M. tuberculosis H37R", M. paratuberculosis.
The object of the present invention is to provide a vaccine containing 'Mycobacterium w' (Mw) with or without constituents obtained from Mw for the prophylaxis against tuberculosis, to a subject exposed to HIV infection or is HIV positive with or without overt symptoms of AIDS.
Yet another object of the invention is to provide a vaccine to convert tuberculin negative individuals who are HIV positive to tuberculin positive status.
Yet another object of the invention is to provide vaccine derived from Mycobacterium w to improve tuberculin status of HIV +ve subjects.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the invention the composition of immunomodulator the method of preparation, HPLC characteristic its safety and tolerability, methods of use-and outcome of treatments are described in following examples.-The following are illustrative examples of the present invention and scope of the present invention should not be limited by them.
Example 1. The pharmaceutical compositions:
A. Each dose of 0.1 ml of therapeutic agent contains:
Mycobacterium w., (heat 0.50 x 109 killed) Sodium Chloride I. P. ... 0.90% w/v .
Tween 80 0.1 % w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. q. s. to 0.1 ml P.
fortuitum subsp fortuitum, M. fortuitum subsp. Peregrinum, M. chelonae subsp. Chelonae, M. chelonae subsp. Abscessus, M. genavense, M.
tuberculosis, M. tuberculosis H37R", M. paratuberculosis.
The object of the present invention is to provide a vaccine containing 'Mycobacterium w' (Mw) with or without constituents obtained from Mw for the prophylaxis against tuberculosis, to a subject exposed to HIV infection or is HIV positive with or without overt symptoms of AIDS.
Yet another object of the invention is to provide a vaccine to convert tuberculin negative individuals who are HIV positive to tuberculin positive status.
Yet another object of the invention is to provide vaccine derived from Mycobacterium w to improve tuberculin status of HIV +ve subjects.
DETAILED DESCRIPTION OF THE INVENTION
In accordance with the invention the composition of immunomodulator the method of preparation, HPLC characteristic its safety and tolerability, methods of use-and outcome of treatments are described in following examples.-The following are illustrative examples of the present invention and scope of the present invention should not be limited by them.
Example 1. The pharmaceutical compositions:
A. Each dose of 0.1 ml of therapeutic agent contains:
Mycobacterium w., (heat 0.50 x 109 killed) Sodium Chloride I. P. ... 0.90% w/v .
Tween 80 0.1 % w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. q. s. to 0.1 ml P.
B. Each dose of 0.1 ml of therapeutic agent contains:
Mycobacterium w., (heat 0.50 x 109 killed) Sodium Chloride I. P. ... 0.90% w/v .
Triton x 100 0.1 % w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. q. s. to 0.1 ml P, C. Each dose of 0.1 ml of therapeutic agent contains:
Mycobacterium w., (heat killed) 0.50 x 109 Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml D. Each dose of 0.1 ml of therapeutic agent contains ._ E.x~+,ract of Mycobacterium~w after. s~nication from 1 x1 C?~°..Mycoba.cte.riurn w_ Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml E. Each dose of 0.1 ml of therapeutic agent contains Methanol Extract of 1x10° Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml s F. Each dose of 0.1 ml of therapeutic agent contains Chloroform Extract of 1x10° Mycobacterium w Sodium Chloride I. P. ... . 0.90% wlv Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml G. Each dose of 0.1 ml of therapeutic agent contains Acetone Extract of 1x10° Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml H. . Each dose of 0.1 ml of therapeutic agent contains Ethanol Extract of 1x10'° Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml I. Each dose of 0.1 ml of therapeutic agent contains Liticase Extract of 1x10'°Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml J. Each dose of 0.1 ml of therapeutic agent contains Mycobacterium w (heat killed) 0.5x10' Extract of mycobacterium w obtained 1x103 Mycobacterium w by disruption, solvent extraction or enzymatic extraction.
Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml Example 2. The Process of preparing a pharmaceutical composition A. Culturing of Mycobacterium w.
i) Preparation of culture medium.
Mycobacterium w is cultured on solid medium like L J medium or liquid medium like middle brook medium or sauton's liquid medium.
For better yield middle brook medium is enriched. It can be preferably enriched by addition of glucose, bactotryptone, and BSA. They are used in ratio of 20:30:2 preferably.
The enrichment medium is added to middle brook medium. It is done preferably in ratio of 15:1 to 25:1 more preperably in ratio of 20:1.
ii) Bioreactor operation a). Preparation of vesse.l.:._~_ The inner contact parts of the vessel (Joints, mechanical seals, o-ring/gasket grooves, etc.) should be properly cleaned to avoid any contamination. Fill up the vessel with 0.1 N NaOH and leave as such for 24 H to remove pyrogenic materials and other contaminants. The vessel is then cleaned first with acidified water, then wit ordinary water. Finally, the vessel is rinsed with distilled water (3 times) before preparing medium.
b) Sterilization of bioreactor The bioreactor containing 9L distilled water is sterilized with live steam(indirect). Similarly the bioreactor is sterilized once more with Middlebrook medium. The other addition bottles, inlet/outlet air filters etc. are autoclaved (twice) at 121°C for 15 minutes. Before use, these are dried at 50° C
oven.
c) Environmental parameter i. Tem~prature: 37~ 0.5° C
ii, pH : 6.7 to 6.8 initially.
B. Harvesting and concentrating It is typically done at the end of 6t" day after culturing under aseptic condition. The concentration of cells (palletisation) is done by centrifugation.
C. Washing of cells The pallet so obtained is washed minimum three times with normal saline. ft can be washed with any other fluid which is preferably isotonic.
D. Adding pharmaceutically acceptable carrier.
Pyrogen free normal saline is added to pallet. Any other pyrogen free isotonic fluid can be used as a pharmaceutical carrier. The carrier is added in amount so as get to desired concentration of active in final form.
E. Adding preservative To keep the product free from other contaminating bacteria for its self life preservative is added. Preferred preservative is thiomesol which is used in final concentration of 0.01 %. w/v.
s F. Terminal Sterilization Terminal sterilization can done by various physical methods like application of heat or ionizing radiation or sterile filtration.
Heat can be in the form of dry heat or moist heat. It can also be in the form of boiling or pasturisation.
Ionizing radiation can be ultraviolet or gamma rays or mircrowave or any other form of ionizing radiation.
It is preferable to autoclave the final product.
This can be done before after filling in a final packagirig.
G. Quality Control i.The material is evaluated for purity, sterility.
ii.The organisms are checked for acid fastness after gram staining.
iii.lnactivation test : This is done by culturing the product on L J
medium to find out any living organism.
iv.Pathogenicity and/or contamination with pathogen.
The cultured organisms are infected to Balb/c mice.
None of the mice should die and all should remain healthy and gain weight. There should not be any macroscopic or microscopic lesions seen in liver, lung spleen or any other organs when animals are killed upto 8 weeks following treatment.
v. Biochemical Test:
The organism is subjected to following biochemical tests:
a) Urease b) Tween 80 hydrolysis c) Niacin test d) Nitrate reduction test The organism gives negative results in urease, tween 80 hydrolysis and niacin test. It is positive by nitrate reduction test.
H. Preparation of constituents of Mycobacterium w.
The constituents of Mycobacterium w can be prepared for the purpose of invention by:
I. Cell disruption II. Solvent extration III. Enzymatic extraction.
The cell disruption can be done by way of sonication or use of high pressure fractionometer or by application of osmotic pressure ingredient.
The solvent extraction can be done by any organic solvent like chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea, hexane etc.
The enzymatic extraction can be done by enzymes which can digest cell wall/membranes. They are typically proteolytic in nature.
Enzyme liticase and pronase are the preferred enzymes. For the purpose of invention cell constituents of Mycobacterium w can be Io used alone in place of mycobacterium w organisms or it can be added to the product containing mycobacterium w.
Addition of cell constituents results in improved efficacy of the p rod a ct.
Example 3. Characteristics of constituents of Mycobacterium w by HPLC analysis.
The constituents of mycobacterium w. used for the purpose of invention when subjected to HPLC analysis gives a single peak at 11 minutes. No other significant peaks are found beyond. The peak is homogenous and devoid of any notch suggesting homogeneity of material obtained HPLC analysis was done using a waters system high performance liquid chromatography apparatus Column: Novapak c1860A, 4~.m, 3.9 x 150mm.
The guard column: Novapak c 18 Column Temperature:30 c Flow rate: 2.5 ml/min Injection volume: 25~.L.
Mobile phase:
Solvent A: HPLC grade methanol.
Solvent B: HPLC grade methylene chloride Binary gradient:
The HPLC gradient initially comprised 98%(v/v) methanol (solvent B).
The gradient was increased linearly to 80%.
A and 20% B at one minute; 35% A and 65% B at 10 minutes, held for 5 seconds and then decreased over 10 seconds back to 98% A and 2% B.
m Example 4. Immunity against tuberculosis in HIV sero positive ~n~~.~~.~~~~m Ten HIV positives (subjects) were enrolled in this study. All of them were tuberculin negative with a tuberculin reading of '0' m.m. and that was the reason of including them in study. All were administered intradermal mycobacterium w.. In all subjects, tuberculin test to determine tuberculin like delayed-type hypersensitivity reaction was repeated after ninety days.
Results of the study are shown in Fig1. In all 10 subjects repeat tuberculin test performed after 90 days revealed a reading of more than 5 m.m. In 8 of 10 subjects it was more than 10 m.m. Maximum reading seen was 17 m.m. and minimum was 6 m. m. The mean reading was 12.6 m.m.
In HIV positive individuals cut-off point for considering an individual tuberculin positive is 5 m.m. thus all the subjects got converted from tuberculin negative status to tuberculin positive status. Thus in all subjects immunity against mycobacterium tuberculosis as determined by tuberculin conversion from negative to positive was obtained after single intradermal injection.
The tuberculin negative status as seen in this study before enrollment is seen in spite of patients having active tuberculosis.
In HIV positive individuals immunity decreases with decrease in CD4 count.
This decreased cell mediated immunity results in change in tuberculin status also. Initialyy tuberculin positive subjects become tuberculin negative with decrease in immunity.
In immunocompetent individuals tuberculosis can be diagnosed by positive tuberculin test in an individual who neither given BCG nor exposed to tuberculosis. Thus tuberculin negativity '0' m.m. reading inspite . of active tuberculosis suggests difficult situation for tuberculin conversion.
The present invention provides tuberculin conversion and immunity against tuberculosis in highly vulnerable group and provides prophylaxis, a much desired effect.
i2
Mycobacterium w., (heat 0.50 x 109 killed) Sodium Chloride I. P. ... 0.90% w/v .
Triton x 100 0.1 % w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. q. s. to 0.1 ml P, C. Each dose of 0.1 ml of therapeutic agent contains:
Mycobacterium w., (heat killed) 0.50 x 109 Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml D. Each dose of 0.1 ml of therapeutic agent contains ._ E.x~+,ract of Mycobacterium~w after. s~nication from 1 x1 C?~°..Mycoba.cte.riurn w_ Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml E. Each dose of 0.1 ml of therapeutic agent contains Methanol Extract of 1x10° Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml s F. Each dose of 0.1 ml of therapeutic agent contains Chloroform Extract of 1x10° Mycobacterium w Sodium Chloride I. P. ... . 0.90% wlv Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml G. Each dose of 0.1 ml of therapeutic agent contains Acetone Extract of 1x10° Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml H. . Each dose of 0.1 ml of therapeutic agent contains Ethanol Extract of 1x10'° Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml I. Each dose of 0.1 ml of therapeutic agent contains Liticase Extract of 1x10'°Mycobacterium w Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml J. Each dose of 0.1 ml of therapeutic agent contains Mycobacterium w (heat killed) 0.5x10' Extract of mycobacterium w obtained 1x103 Mycobacterium w by disruption, solvent extraction or enzymatic extraction.
Sodium Chloride I. P. ... . 0.90% w/v Thiomerosal I. P. ... . 0.01 % w/v (As a Preservative) Water for injection I. P. q. s. to 0.1 ml Example 2. The Process of preparing a pharmaceutical composition A. Culturing of Mycobacterium w.
i) Preparation of culture medium.
Mycobacterium w is cultured on solid medium like L J medium or liquid medium like middle brook medium or sauton's liquid medium.
For better yield middle brook medium is enriched. It can be preferably enriched by addition of glucose, bactotryptone, and BSA. They are used in ratio of 20:30:2 preferably.
The enrichment medium is added to middle brook medium. It is done preferably in ratio of 15:1 to 25:1 more preperably in ratio of 20:1.
ii) Bioreactor operation a). Preparation of vesse.l.:._~_ The inner contact parts of the vessel (Joints, mechanical seals, o-ring/gasket grooves, etc.) should be properly cleaned to avoid any contamination. Fill up the vessel with 0.1 N NaOH and leave as such for 24 H to remove pyrogenic materials and other contaminants. The vessel is then cleaned first with acidified water, then wit ordinary water. Finally, the vessel is rinsed with distilled water (3 times) before preparing medium.
b) Sterilization of bioreactor The bioreactor containing 9L distilled water is sterilized with live steam(indirect). Similarly the bioreactor is sterilized once more with Middlebrook medium. The other addition bottles, inlet/outlet air filters etc. are autoclaved (twice) at 121°C for 15 minutes. Before use, these are dried at 50° C
oven.
c) Environmental parameter i. Tem~prature: 37~ 0.5° C
ii, pH : 6.7 to 6.8 initially.
B. Harvesting and concentrating It is typically done at the end of 6t" day after culturing under aseptic condition. The concentration of cells (palletisation) is done by centrifugation.
C. Washing of cells The pallet so obtained is washed minimum three times with normal saline. ft can be washed with any other fluid which is preferably isotonic.
D. Adding pharmaceutically acceptable carrier.
Pyrogen free normal saline is added to pallet. Any other pyrogen free isotonic fluid can be used as a pharmaceutical carrier. The carrier is added in amount so as get to desired concentration of active in final form.
E. Adding preservative To keep the product free from other contaminating bacteria for its self life preservative is added. Preferred preservative is thiomesol which is used in final concentration of 0.01 %. w/v.
s F. Terminal Sterilization Terminal sterilization can done by various physical methods like application of heat or ionizing radiation or sterile filtration.
Heat can be in the form of dry heat or moist heat. It can also be in the form of boiling or pasturisation.
Ionizing radiation can be ultraviolet or gamma rays or mircrowave or any other form of ionizing radiation.
It is preferable to autoclave the final product.
This can be done before after filling in a final packagirig.
G. Quality Control i.The material is evaluated for purity, sterility.
ii.The organisms are checked for acid fastness after gram staining.
iii.lnactivation test : This is done by culturing the product on L J
medium to find out any living organism.
iv.Pathogenicity and/or contamination with pathogen.
The cultured organisms are infected to Balb/c mice.
None of the mice should die and all should remain healthy and gain weight. There should not be any macroscopic or microscopic lesions seen in liver, lung spleen or any other organs when animals are killed upto 8 weeks following treatment.
v. Biochemical Test:
The organism is subjected to following biochemical tests:
a) Urease b) Tween 80 hydrolysis c) Niacin test d) Nitrate reduction test The organism gives negative results in urease, tween 80 hydrolysis and niacin test. It is positive by nitrate reduction test.
H. Preparation of constituents of Mycobacterium w.
The constituents of Mycobacterium w can be prepared for the purpose of invention by:
I. Cell disruption II. Solvent extration III. Enzymatic extraction.
The cell disruption can be done by way of sonication or use of high pressure fractionometer or by application of osmotic pressure ingredient.
The solvent extraction can be done by any organic solvent like chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea, hexane etc.
The enzymatic extraction can be done by enzymes which can digest cell wall/membranes. They are typically proteolytic in nature.
Enzyme liticase and pronase are the preferred enzymes. For the purpose of invention cell constituents of Mycobacterium w can be Io used alone in place of mycobacterium w organisms or it can be added to the product containing mycobacterium w.
Addition of cell constituents results in improved efficacy of the p rod a ct.
Example 3. Characteristics of constituents of Mycobacterium w by HPLC analysis.
The constituents of mycobacterium w. used for the purpose of invention when subjected to HPLC analysis gives a single peak at 11 minutes. No other significant peaks are found beyond. The peak is homogenous and devoid of any notch suggesting homogeneity of material obtained HPLC analysis was done using a waters system high performance liquid chromatography apparatus Column: Novapak c1860A, 4~.m, 3.9 x 150mm.
The guard column: Novapak c 18 Column Temperature:30 c Flow rate: 2.5 ml/min Injection volume: 25~.L.
Mobile phase:
Solvent A: HPLC grade methanol.
Solvent B: HPLC grade methylene chloride Binary gradient:
The HPLC gradient initially comprised 98%(v/v) methanol (solvent B).
The gradient was increased linearly to 80%.
A and 20% B at one minute; 35% A and 65% B at 10 minutes, held for 5 seconds and then decreased over 10 seconds back to 98% A and 2% B.
m Example 4. Immunity against tuberculosis in HIV sero positive ~n~~.~~.~~~~m Ten HIV positives (subjects) were enrolled in this study. All of them were tuberculin negative with a tuberculin reading of '0' m.m. and that was the reason of including them in study. All were administered intradermal mycobacterium w.. In all subjects, tuberculin test to determine tuberculin like delayed-type hypersensitivity reaction was repeated after ninety days.
Results of the study are shown in Fig1. In all 10 subjects repeat tuberculin test performed after 90 days revealed a reading of more than 5 m.m. In 8 of 10 subjects it was more than 10 m.m. Maximum reading seen was 17 m.m. and minimum was 6 m. m. The mean reading was 12.6 m.m.
In HIV positive individuals cut-off point for considering an individual tuberculin positive is 5 m.m. thus all the subjects got converted from tuberculin negative status to tuberculin positive status. Thus in all subjects immunity against mycobacterium tuberculosis as determined by tuberculin conversion from negative to positive was obtained after single intradermal injection.
The tuberculin negative status as seen in this study before enrollment is seen in spite of patients having active tuberculosis.
In HIV positive individuals immunity decreases with decrease in CD4 count.
This decreased cell mediated immunity results in change in tuberculin status also. Initialyy tuberculin positive subjects become tuberculin negative with decrease in immunity.
In immunocompetent individuals tuberculosis can be diagnosed by positive tuberculin test in an individual who neither given BCG nor exposed to tuberculosis. Thus tuberculin negativity '0' m.m. reading inspite . of active tuberculosis suggests difficult situation for tuberculin conversion.
The present invention provides tuberculin conversion and immunity against tuberculosis in highly vulnerable group and provides prophylaxis, a much desired effect.
i2
Claims (32)
1. A method of providing immunity against tuberculosis in HIV positive individuals comprises administration of a formulation which is prepared using Mycobacterium w or a pharmaceutical composition obtained from Mycobacterium w alone or in combination and also with or without adjuvants to a subject who is HIV positive.
2. The method as claimed in claim 1 for providing immunity against tuberculosis in HIV positive individuals is effective converting tuberculin negative individuals to tuberculin positive individuals.
3. The method as claimed in claim 1 for providing immunity against tuberculosis in HIV positive individuals is effective in improving tuberculin status of treated individuals.
4. The product as claimed in claim 1 contain mycobacterium w is killed mycobacterium w.
5. The Mycobacterium w as claimed in claim 1 and 2 is killed by physical method like, heat radiation most preferably by heat in form of autoclaving.
6. The product as claimed in claim 1 is obtained from mycobacterium w by sonication.
7. The product as claimed in claim 1 is obtained from mycobacterium w by extraction.
8. The product as claimed in claim 1 and 5 is obtained from mycobacterium w is extracted by organic solvents.
9. The product as claimed in claim 1, 5 and 6 is extracted using solvent selected from chloroform, ethanol, methanol, acetone, phenol, isopropyl alcohol, acetic acid, urea, Hexane and like.
10. The adjuvants as claimed in claim 1 is selected from mineral oil, mineral oil and surfactant, Ribi adjuvant, Titer-max, syntax adjuvant formulation, aluminium salt adjuvant, nitrocellulose adsorbed antigen, immune stimulating complexes, Gebru adjuvant, super carrier, elvax 40w, L -tyrosine, monatanide (manide -oleate compound), Adju prime, Squalene, Sodium phthalyl lipopoly saccharide, calcium phosphate, saponin, melanoma antigen, muramyl dipeptide(MDP) and like.
11. The formulation as claimed in claim 1 contains surfactant.
12. The surfactant as claimed in claim 9 can be a Tween 80.
13. The amount of surfactant as claimed in claim 9 and 10 is upto 0.4%
preferably 0.1%.
preferably 0.1%.
14. The formulation as claimed in claim1 containing mycobacterium w or obtained from mycobacterium w or combination of both with or without adjuvants helps in amelioration of symptoms of cancer.
15. The formulation as claimed in claim1 containing mycobacterium w or obtained from mycobacterium w or combination of both with or without adjuvants are capable of causing regression or even complete control of cancer.
16. The Mycobacterium w as claimed in claim 1,2,3,4,5,6 is a non-pathogenic, fast growing cultivable, atypical mycobacterium, with biochemical properties and growth characteristics resembling those belonging to Runyons group IV class of Mycobacteria in its metabolic and growth properties but is not identical to those strains currently listed in this group.
17. Mycobacterium w as claimed in claim 1 is urease negative, does not hydrolyse tween 80, does not produce niacin, provides strong positive response to nitrate reduction test.
18. The cancerous tissue as claimed in claim 17 can be a primary or a secondary(metastatic) lesion.
19. The method as claimed in claim 1 is effective in reducing side effects of other cancer therapies like radiotherapy, chemotherapy.
20. The administration of formulation as claimed in claim 1 is by parental route.
21. The administration as claimed in claim 1 and 17 is by intramuscular subcutaneous, intradermal route and like but preferably by intradermal route.
22. The amount of mycobacterium w administered at a time to a subject as claimed in claim 1 is equal to or more than 1× 10 5 mycobacterium w.
23. The amount of mycobacterium w administered at a time to a subject as claimed in claim 1 is equal to or more than 10 7 mycobacterium w.
24. The amount of mycobacterium w administered at a time to a subject as claimed in claim 1 is most preferably 1× 10 8 to 1× 10 10 mycobacterium w.
25.The process of manufacturing a pharmaceutical composition useful for management of cancer comprises of incorporating cells of mycobacterium w alongwith pharmaceutically acceptable carrier and optionally a preservative in a single formulation wherein cells of mycobacterium w are not alive.
26. The pharmaceutically acceptable carrier as claimed in clain 1 is added in a way so as to have more than or equal to 1× 10 5 mycobacterium w in a unitary dosage, more preferably equal to or more than 1×10 7 mycobacterium w in unitary dosage most preferably between 1×10 8 to 1×10 9 cells of mycobacterium w in a unitary dosage form.
27. The process of manufacturing a pharmaceutical composition useful for management of cancer comprising the steps of incorporating disrupted cells of mycobacterium w along with pharmaceutically acceptable carrier and optionally a preservative.
28. The process of manufacturing a pharmaceutical composition useful for management of cancer comprising the steps of incorporating solvent extraction of mycobacterium w along with pharmaceutically acceptable carrier and optionally a preservative.
29. The process of manufacturing a pharmaceutical composition useful for management of cancer comprising of incorporating enzymatic extraction of mycobacterium w along with pharmaceutically acceptable carrier and optionally a preservative
30. The process of manufacturing a pharmaceutical composition useful for management of cancer comprising admixing product of claim 1 with product of claim 31 and/or claim 32 and/or claim 33.
31. The process of manufacturing a pharmaceutical composition useful for management of cancer comprise of adding adjuvant to product of claim 1, claim 4, claim 6, claim 8 or claim 10.
32. The adjuvant as claimed in claim 17 is selected from mineral oil, mineral oil and surfactant, Ribi adjuvant, Titer-max, syntax adjuvant formulation, aluminium salt adjuvant, nitrocellulose adsorbed antigen, immune stimulating complexes, Gebru adjuvant, super carrier, elvax 40w, L -tyrosine, monatanide (manide -oleate compound), Adju prime, Squalene, Sodium phthalyl lipopoly saccharide, calcium phosphate, saponin, melanoma antigen, muramyl dipeptide(MDP) and like.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN81MU2002 | 2002-01-29 | ||
| IN81/MUM/2002 | 2002-01-29 | ||
| PCT/IB2003/000207 WO2003063897A1 (en) | 2002-01-29 | 2003-01-27 | Method of providing prophylaxis for tuberculosis in hiv positive individuals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2474794A1 true CA2474794A1 (en) | 2003-08-07 |
Family
ID=27638225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002474794A Abandoned CA2474794A1 (en) | 2002-01-29 | 2003-01-27 | Method of providing prophylaxis for tuberculosis in hiv positive individuals |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1478391A1 (en) |
| JP (1) | JP2006502090A (en) |
| AP (1) | AP2004003109A0 (en) |
| BR (1) | BR0307262A (en) |
| CA (1) | CA2474794A1 (en) |
| EA (1) | EA200400997A1 (en) |
| GB (1) | GB2400560A (en) |
| WO (1) | WO2003063897A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003209534A1 (en) * | 2002-03-08 | 2003-09-22 | Bakulesh Mafatlal Khamar | The method of treating tuberculosis |
| ES2231037B1 (en) | 2003-10-31 | 2005-12-16 | Archivel Technologies, Sl | USEFUL IMMUNOTHERAPIC AGENT FOR THE COMBINED TREATMENT OF TUBERCULOSIS IN ASSOCIATION WITH OTHER PHARMACOS. |
| ES2307402B1 (en) | 2006-10-30 | 2009-09-30 | Archivel Farma, S.L. | PROFILACTIC VACCINE AGAINST TUBERCULOSIS. |
| US20100209394A1 (en) * | 2007-06-28 | 2010-08-19 | Cadila Pharmaceuticals Ltd. | Mitogen activated protein kinase modulator |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9219425D0 (en) * | 1992-09-14 | 1992-10-28 | Univ London | Therapeutic agent and its use |
| GB8918206D0 (en) * | 1989-08-09 | 1989-09-20 | Nat Inst Immunology | Tuberculosis vaccine |
| KR20050008453A (en) * | 2002-03-08 | 2005-01-21 | 바쿠레시 마파탈 카마르 | Process of manufacturing pharmaceutical composition useful for management of tuberculosis |
-
2003
- 2003-01-27 CA CA002474794A patent/CA2474794A1/en not_active Abandoned
- 2003-01-27 JP JP2003563586A patent/JP2006502090A/en active Pending
- 2003-01-27 BR BRPI0307262-2A patent/BR0307262A/en not_active IP Right Cessation
- 2003-01-27 AP APAP/P/2004/003109A patent/AP2004003109A0/en unknown
- 2003-01-27 EA EA200400997A patent/EA200400997A1/en unknown
- 2003-01-27 GB GB0418776A patent/GB2400560A/en not_active Withdrawn
- 2003-01-27 EP EP03701636A patent/EP1478391A1/en not_active Withdrawn
- 2003-01-27 WO PCT/IB2003/000207 patent/WO2003063897A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2006502090A (en) | 2006-01-19 |
| EA200400997A1 (en) | 2005-12-29 |
| WO2003063897A8 (en) | 2005-03-31 |
| AP2004003109A0 (en) | 2004-09-30 |
| GB2400560A (en) | 2004-10-20 |
| EP1478391A1 (en) | 2004-11-24 |
| WO2003063897A1 (en) | 2003-08-07 |
| GB0418776D0 (en) | 2004-09-22 |
| BR0307262A (en) | 2006-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0556241B1 (en) | Mycobacterium vaccae in the treatment of uveitis | |
| Collins | The immunology of tuberculosis | |
| CA2469266C (en) | The method of treating cancer | |
| WO2003049751A1 (en) | The process of manufacturing a pharmaceutical composition useful for management of cancer | |
| Shepard | The first decade in experimental leprosy | |
| CA2474794A1 (en) | Method of providing prophylaxis for tuberculosis in hiv positive individuals | |
| WO2003075824A2 (en) | Process of manufacturing pharmaceutical composition useful for management of tuberculosis | |
| WO2003063896A1 (en) | Process of preparing a pharmaceutical composition for immunity against tuberculosis in hiv positive individuals | |
| WO2010031883A1 (en) | Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis | |
| WO2003075825A2 (en) | The method of treating tuberculosis | |
| AU2003202725A1 (en) | Method of providing prophylaxis for tuberculosis in HIV positive individuals | |
| KR102044585B1 (en) | Inactivated mycobacteria for oral use in the prevention of tuberculosis | |
| Julián et al. | Bacteria-Derived Alternatives to Live Mycobacterium bovis Bacillus Calmette–Guerin for Nonmuscle Invasive Bladder Cancer Treatment | |
| AU2002225263B2 (en) | Use of mycobacterium W for the treatment of human immunodeficiency virus (HIV) disease infection | |
| Watson et al. | Delayed hypersensitivity responses in mice and guinea pigs to Mycobacterium leprae, Mycobacterium vaccae, and Mycobacterium nonchromogenicum cytoplasmic proteins | |
| EP1368044B1 (en) | Immunomodulator for the management of human immunodeficiency virus (hiv) disease/infection | |
| US8153102B2 (en) | Process for manufacturing pharmaceutical composition comprises of Mycobacterium w in the treatment of asthma (obstructive lung disease) | |
| WO2003075827A2 (en) | Use of mycobacterium w in the treatment of asthama(obstructive lung disease) | |
| AU2002225263A1 (en) | Use of mycobacterium W for the treatment of human immunodeficiency virus (HIV) disease infection | |
| Bennedsen et al. | The BCG‐induced resistance to listeriosis | |
| Carter | Department of Microbiology and Lobund Laboratory University of Notre Dame, Notre Dame, Indiana 46556, USA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |